| Enzo Biochem's Clinical Labs Unit Enters into Co-Marketing Program with MMF Systems, Inc., for Web-Based Medical Records and Practice Management Software (Business Wire) NEW YORK----Enzo Biochem, Inc., announced today that Enzo Clinical Labs, Inc., its reference lab division serving physicians and medical facilities in the New York metropolitan area, has entered into a trial co-marketing services agreement with privately-owned MMF Systems, Inc. , of New York City, involving MMF’S state of the art medical records system. us.rd.yahoo.com |
Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes The Burrill Report submits: GlaxoSmithKline (GSK) said that it expects to record a legal charge for the second quarter of 2010 of $2.36 billion relating to settlements of product liability litigation concerning its diabetes drug Avandia and anti-trust litigations relating to Paxil and other products, as well as the U.S. government’s investigation into its former manufacturing facility in Cidra, Puerto Rico. The company confirms it has reached an agreement in principle with the U.S. Attorney’s Office for the District of Massachusetts and the U.S. Department of Justice to pay a total of $750 million in the settlement of the Cidra investigation. The legal charge announced includes provisioning for settled cases and an estimate for those cases which GSK has received and are still outstanding. Terms of the settlements reached are confidential. The charge also includes provisioning relating to other legal matters. The U.S. subsidiary of Novartis Pharmaceuticals (NVS) said it agreed to pay $152.5 million as part of a settlement of alleged sexual discrimination. In addition, the company will fund improvements to policies and programs with approximately an additional $22.5 million. Novartis contends that the alleged behavior described during the trial in the Southern District of New York is not systemic, but acknowledged there had been problems.Complete Story » seekingalpha.com |
Genomic Health Announces Second Quarter 2010 Financial Results and Business Progress (PR Newswire) Genomic Health, Inc. today reported financial results and business progress for the quarter ended June 30, 2010. us.rd.yahoo.com |
U.S. Reviews FDA Scientists' Complaints Federal inspectors have reopened a review of complaints by FDA scientists who say they were pressured by their managers to approve some high-tech medical devices, overriding their concerns about potential harm to patients. online.wsj.com |
Good News Keeps Coming for Amgen With Aranesp Vote EP Vantage submits:Amgen (AMGN) stands tall. A threat that a US expert panel would vote to tighten the use of its red blood cell booster Aranesp has faded away, another in a string of victories the world’s biggest biotech has scored in recent months to preserve its vital franchise in erythropoietin-stimulating agents (ESAs).While there is no doubt that safety concerns have undermined the California company’s stronghold, several regulatory and competitive threats have dissipated in recent months. As such, when an FDA advisory panel voted Monday to largely preserve the Aranesp label for chronic kidney disease (CKD) patients, Amgen investors and executives must have breathed a sigh of relief, as evidenced by a 2% rise in Amgen’s shares.Complete Story » seekingalpha.com |